New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Lilly announced that EBGLYSS met its primary endpoint in the Phase 3b ADtouch study, with 53% of patients achieving clear or almost clear hand and foot skin at Week 16 versus 27% on placebo. The trial also showed rapid itch and pain relief, with significant improvements as early as one to two weeks, and 77% patient satisfaction with hand clearance versus 40% for placebo; no new safety signals were observed.
Key figures
- Drug Name
- EBGLYSS (lebrikizumab-lbkz)
- Phase Of Trial
- Phase 3b
- Hf iga 0 1 week4
- 17% vs 6% placebo
- Hf iga 0 1 week16
- 53% vs 27% placebo
- Patients randomized
- 221
- Itch response week16
- 57% vs 19% placebo
- Pain response week16
- 59% vs 19% placebo
- Rescue medication use
- 6% vs 18% placebo
- Treatment emergent aes
- 41.8% EBGLYSS vs 39.6% placebo
- Patient satisfaction week16
- 77% vs 40% placebo
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.